FY2019 EPS Estimates for Syndax Pharmaceuticals Inc Increased by Analyst (SNDX)

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) – Equities researchers at Oppenheimer raised their FY2019 EPS estimates for shares of Syndax Pharmaceuticals in a research note issued to investors on Monday, October 29th. Oppenheimer analyst H. Singh now forecasts that the company will earn ($3.99) per share for the year, up from their previous forecast of ($4.63). Oppenheimer also issued estimates for Syndax Pharmaceuticals’ FY2020 earnings at ($4.02) EPS, FY2021 earnings at ($3.97) EPS and FY2022 earnings at $0.37 EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, August 7th. The company reported ($0.74) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.13. The firm had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.38 million. Syndax Pharmaceuticals had a negative return on equity of 80.35% and a negative net margin of 3,190.51%.

A number of other equities research analysts have also commented on the company. Zacks Investment Research lowered Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, September 13th. HC Wainwright initiated coverage on Syndax Pharmaceuticals in a research report on Thursday, July 12th. They issued a “buy” rating and a $30.00 target price on the stock. Citigroup lowered their price objective on Syndax Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, October 11th. ValuEngine upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, July 6th. Finally, Morgan Stanley lowered Syndax Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $6.00 price objective on the stock. in a research report on Monday. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $18.20.

Shares of NASDAQ SNDX opened at $4.77 on Wednesday. The company has a market capitalization of $117.01 million, a P/E ratio of -1.64 and a beta of 1.28. Syndax Pharmaceuticals has a 52 week low of $4.36 and a 52 week high of $15.20.

A number of institutional investors have recently added to or reduced their stakes in SNDX. BlackRock Inc. boosted its position in Syndax Pharmaceuticals by 11.0% in the 1st quarter. BlackRock Inc. now owns 1,276,671 shares of the company’s stock worth $18,168,000 after purchasing an additional 126,941 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Syndax Pharmaceuticals by 77.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 397,579 shares of the company’s stock worth $5,658,000 after purchasing an additional 173,821 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Syndax Pharmaceuticals by 266.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 10,566 shares of the company’s stock worth $151,000 after purchasing an additional 7,686 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its stake in shares of Syndax Pharmaceuticals by 433.3% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 70,140 shares of the company’s stock worth $492,000 after buying an additional 56,988 shares during the period. Finally, Aviva PLC acquired a new position in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $423,000. Institutional investors and hedge funds own 64.29% of the company’s stock.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.

Featured Story: How to Invest in a Bull Market

Earnings History and Estimates for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply